国际肿瘤学杂志

国际肿瘤学杂志 ›› 2012, Vol. 39 ›› Issue (3): 190-193.

• 综述 • 上一篇    下一篇

外周T细胞淋巴瘤抗血管生成研究进展

万珊,顾康生   

  1. 230022合肥，安徽医科大学第一附属医院肿瘤内科
  • 出版日期:2012-03-08 发布日期:2012-02-24

Antiangiogenic therapy for PTCL

WAN  Shan, GU  Kang-Sheng   

  1. Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
  • Online:2012-03-08 Published:2012-02-24

PDF

1813

被引次数

1

摘要： 外周T细胞淋巴瘤（PTCL）对传统的化疗方案不敏感，与B细胞淋巴瘤相比预后差，目前缺乏有效的治疗方案。血管生成在恶性肿瘤的生长过程中具有重要的作用，研究显示血管内皮生长因子（VEGF）的表达与PTCL的临床特征及预后相关。同时，具有抗血管生成作用的药物在PTCL的初步临床研究中显示出了疗效。

关键词: color: green, font-family: 宋体, position: relative, top: -1pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-bidi-font-family: 'Times New Roman', mso-font-kerning: 1.0pt, mso-text-raise: 1.0pt">淋巴瘤,T细胞,外周, 血管内皮生长因子类, 血管生成抑制剂, 沙立度胺, 缺氧诱导因子1

Abstract: Peripheral T-cell lymphomas (PTCLs) are insensitive to traditional chemotherapies, and are lack of effective treatments and have worse prognosisthan B-cell lymphomas. Angiogenesis plays an essential role in the malignant tumor growth. Recently, studies have shown that the expression level of VEGF is related to the clinical characteristic and prognosis of PTCL. Novel drugs based on anti-angiogenic theory show curative effect in the preliminary clinical trials for the treatment of PTCL.

Key words: color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-font-kerning: 1.0pt">Lymphoma,color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-font-kerning: 1.0pt">T-cell,color: green, font-family: "Times New Roman", mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-font-kerning: 1.0pt">peripheral, Vascular endothelial growth factors, Angiogenesis inhibitors, Thalidomide, Hypoxia-inducible factor 1